Amalgamated Bank Adverum Biotechnologies, Inc. Transaction History

Amalgamated Bank

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $8,471 - $14,015	-10,459 Closed	0 $0
Q1 2022 Jun 30, 2022	SELL	$1.23 - $1.95 $1,047 - $1,661	-852 Reduced 7.53%	10,459 $14,000
Q4 2021 Feb 15, 2022	SELL	$1.74 - $2.4 $673 - $928	-387 Reduced 3.31%	11,311 $20,000
Q3 2021 Oct 29, 2021	SELL	$2.08 - $3.6 $1,102 - $1,908	-530 Reduced 4.33%	11,698 $25,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $924 - $2,904	275 Added 2.3%	12,228 $43,000
Q1 2021 May 13, 2021	SELL	$9.26 - $14.36 $9,750 - $15,121	-1,053 Reduced 8.1%	11,953 $118,000
Q4 2020 Feb 12, 2021	BUY	$9.84 - $14.26 $4,801 - $6,958	488 Added 3.9%	13,006 $140,000
Q3 2020 Oct 30, 2020	BUY	$10.3 - $21.64 $16,335 - $34,321	1,586 Added 14.51%	12,518 $129,000
Q2 2020 Aug 10, 2020	BUY	$8.53 - $25.64 $1,654 - $4,974	194 Added 1.81%	10,932 $228,000
Q1 2020 May 13, 2020	BUY	$7.98 - $16.32 $4,476 - $9,155	561 Added 5.51%	10,738 $105,000
Q4 2019 Feb 13, 2020	BUY	$5.12 - $12.22 $52,106 - $124,362	10,177 New	10,177 $117,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $451M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

Stay updated on Amalgamated Bank with notifications on news.